Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 7454.

https://doi.org/10.1182/blood-2025-7454

Published: 2025

Journal Articles

Tolerability and long-term survival of fragile or older patients with diffuse large B cell lymphoma (DLBCL) not otherwise specified by R-CDOP

Changtai Tian, Luke Li, Mina Zheng, Rubin Guo, Thomas Jandl, Theodore Gabig, Michael Schuster, Suhu Liu, Christina Lee, Fengshuo Lan

Blood (2025) 146 (Supplement 1): 7223.

https://doi.org/10.1182/blood-2025-7223

Published: 2025

Journal Articles

Retrospective analysis of R-CDOP efficacy and safety in frail patients with DLBCL compared to R-CHOP in fit patients

Luke Li, Changtai Tian, Mina Zheng, Rubin Guo, Thomas Jandl, Theodore Gabig, Michael Schuster, Christina Lee, Suhu Liu, Fengshuo Lan

Blood (2025) 146 (Supplement 1): 7205.

https://doi.org/10.1182/blood-2025-7205

Published: 2025

Journal Articles

Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Blood (2025) 146 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2025-5763

Published: 2025